MAP2K7 and thyroid gland carcinoma: Thyroid cancers with BRAF mutation were preferentially sensitive to MEK inhibitors (PD0325901, AZD6244) whereas tumors with other MEK-ERK effector pathway gene mutations have variable responses [25].